Intensive Cholesterol Treatment Cuts Heart Plaque 20%
For adults with coronary artery disease, aggressive LDL lowering appears to slow the artery buildup behind heart attacks.
Updated on Nov. 4, 2026 in Heart Disease

Live Poll
Do you think your heart health is getting better or worse for you personally?
A study published in October showed that intensive cholesterol treatment reduced plaque in heart patients' coronary arteries by about 20% over 18 months. The findings add to growing evidence that aggressive LDL lowering may slow the buildup of artery blockages in people with established heart disease.
Why it matters
Heart disease remains the leading cause of death in America, and plaque buildup is the underlying process behind many heart attacks, so slowing it is a central goal of prevention. The result strengthens the case for more intensive lipid-lowering in people who already have coronary artery disease, where prevention has the most at stake.
The October study tracked coronary artery plaque in heart patients receiving intensive cholesterol treatment and found an average reduction of about 20% over 18 months. The extraction does not specify the trial design, sample size or comparison group, so the figure should be read as an early marker of plaque change rather than proof of fewer cardiac events.
The players
Repatha
A PCSK9 inhibitor injection used to lower LDL cholesterol and reduce cardiovascular risk.
Andreessen Horowitz
A venture capital firm that published The State of Longevity report identifying cardiovascular prevention business opportunities.
The details
PCSK9 inhibitors such as Repatha help the liver clear LDL, the so-called bad cholesterol, from the bloodstream by increasing the number of receptors that pull it out of circulation. In a separate study of people with diabetes but no known major artery disease, adding Repatha to existing treatment reduced the estimated five-year risk of a first heart attack, stroke or death from coronary heart disease by 31%. Injections, costs and insurance restrictions have kept use of these drugs limited, though Lipfendra, the first PCSK9 inhibitor available as a daily pill, received FDA approval in July 2026.
Timeline
July 2026: Lipfendra received FDA approval as the first daily PCSK9 pill.
October 2026: A study showed about 20% coronary plaque reduction over 18 months.
Health Landscape
Statins built the foundation of cholesterol-lowering prevention, and PCSK9 inhibitors now offer a more potent option for patients whose LDL remains high. Newer agents aimed at lipoprotein(a), which roughly one in five people carries at elevated levels, are part of a pipeline that could expand prevention beyond conventional LDL targets.
If you have coronary artery disease or high LDL, the findings are worth raising with your doctor at your next visit, particularly whether a more intensive lipid-lowering approach fits your situation. Lipoprotein(a) testing is recommended at least once in adulthood under U.S. guidelines, so it is a reasonable question to bring up with your physician.
The takeaway
Slowing plaque buildup is a meaningful goal in heart disease prevention, and cholesterol treatment is one of the strongest tools available. Ask your physician whether your LDL and lipoprotein(a) levels have been checked and what a target range should be for you.
Further reading
Explore more on Heart Disease to see how plaque reduction fits into broader cardiac prevention.
Source note: This article includes information reported by TokenPost.
Live Poll
Do you think your heart health is getting better or worse for you personally?





